QUICKLINKS AND VIEW OPITONS
Taranabant : 12 mg increases metabolism 6% for three hours
Wednesday, March 12, 2008 7:28 am Email this article
In a one-day, one dose study, 12 mg of taranabant increased resting metabolism by 6 percent for three hours compared to 3 percent for when they were given 30 of Meridia ( sibutramine ). 2-6 mg Not Tested
Doses lower than 12 mg not tested
The paper did not mention lower doses such as 2-6 mg, therefore, I assume that they had no effect on metabolism.
I imagine the drug company knew that this was the case and, therefore, did not test it for this reason.
Metabolism Measured 2-5 Hours After Drug
Metabolism measured 2-5 hours after the drug was given
Metabolism was measured 2-5 hours after the drug was given.
This may not be a completely fair comparison with Meridia, because Meridia may have a larger increase on metabolism during the 1-2 hours after the drug is taken which was not measured in this study.
Again, I imagine the drug company knew this, and therefore tested it this way to make their drug look as good as possible.
Comment : Drug companies do this to make their drug look as good as possible
Unfortunately, most review papers will simply repeat this information and suggest that taranabant may increase metabolism even though it appears that if the drug gets approved, the recommended dose will probably be 2-6 mg, and not the 12 mg tested for it’s effect on metabolism.
Comment : A similar thing happened with Meridia
A similar thing happened with Meridia ( sibutramine ).
They found that Meridia has no effect on serotonin reuptake except in higher-than-recommended-dose of 20 mg or more. ( The recommended dose of Meridia is 5-15 mg. )
Yet, every review paper I read in the medical journals said that Meridia is both a serotonin and noradrenaline reuptake inhibitor.
No, it’s not. Not at the recommended doses.
It only inhibits noradrenaline at the recommended doses of 15 mg or less.
Yet, every one of these very smart people writing these papers fell for this trick and they all said Meridia is both a serotonin and noradrenaline reuptake inhibitor.
The reason the drug company promoted this misinformation is because people are very familiar with and feel very comfortable with serotonin reuptake inhibitors such as Prozac ( fluoxetine ), Zoloft ( sertraline ), etc.
Subjects : 36 overweight and obese people
The study involved 36 overweight and moderately obese people.
Each person was given placebo, 4 mg of taranabant, 12 mg of taranabant and 30 mg of Meridia ( sibutramine ) on different occasions so that each person acted as their own control.
Addy C, Wright H, Laere KV, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, Lepeleire ID, Cilissen C, Cote J, Rosko K, III ING, Nguyen AM, Gumbiner B, Rothenberg P, Hoon JD, Bormans G, Depré M, Eng W-S, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB. The acyclic cb1r inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008 Jan, 7(1):1-2.
AUTHOR’S CONTACT INFORMATION
Steven B. Heymsﬁeld, M.D.
Merck Research Laboratories
Rahway, NJ 07065, USA
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.